These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 26770305)

  • 41.
    Wang S; Chen J; Guo XZ
    World J Gastrointest Oncol; 2022 Aug; 14(8):1388-1405. PubMed ID: 36160748
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lysophosphatidylcholine induces neuropathic pain through an action of autotaxin to generate lysophosphatidic acid.
    Inoue M; Xie W; Matsushita Y; Chun J; Aoki J; Ueda H
    Neuroscience; 2008 Mar; 152(2):296-8. PubMed ID: 18280050
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Clinical introduction of lysophosphatidic acid and autotaxin assays].
    Yatomi Y
    Rinsho Byori; 2010 Jun; 58(6):631-5. PubMed ID: 20662276
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mesenteric Adipose Tissue Contributes to Intestinal Fibrosis in Crohn's Disease Through the ATX-LPA Axis.
    Huang L; Qian W; Xu Y; Guo Z; Yin Y; Guo F; Zhu W; Li Y
    J Crohns Colitis; 2022 Aug; 16(7):1124-1139. PubMed ID: 35104318
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The autotaxin-lysophosphatidic acid-lysophosphatidic acid receptor cascade: proposal of a novel potential therapeutic target for treating glioblastoma multiforme.
    Tabuchi S
    Lipids Health Dis; 2015 Jun; 14():56. PubMed ID: 26084470
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Structural Binding Mode of the Four Autotaxin Inhibitor Types that Differentially Affect Catalytic and Non-Catalytic Functions.
    Salgado-Polo F; Perrakis A
    Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31623219
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Autotaxin and Lysophosphatidate Signaling: Prime Targets for Mitigating Therapy Resistance in Breast Cancer.
    Benesch MGK; Tang X; Brindley DN; Takabe K
    World J Oncol; 2024 Feb; 15(1):1-13. PubMed ID: 38274724
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Autotaxin promotes cancer invasion via the lysophosphatidic acid receptor 4: participation of the cyclic AMP/EPAC/Rac1 signaling pathway in invadopodia formation.
    Harper K; Arsenault D; Boulay-Jean S; Lauzier A; Lucien F; Dubois CM
    Cancer Res; 2010 Jun; 70(11):4634-43. PubMed ID: 20484039
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Structure-function relationships of autotaxin, a secreted lysophospholipase D.
    Hausmann J; Perrakis A; Moolenaar WH
    Adv Biol Regul; 2013 Jan; 53(1):112-7. PubMed ID: 23069371
    [TBL] [Abstract][Full Text] [Related]  

  • 50. ATX and LPA receptor 3 are coordinately up-regulated in lipopolysaccharide-stimulated THP-1 cells through PKR and SPK1-mediated pathways.
    Li S; Xiong C; Zhang J
    FEBS Lett; 2012 Mar; 586(6):792-7. PubMed ID: 22314276
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Identification of Potent
    Kawaguchi M; Okabe T; Okudaira S; Hama K; Kano K; Nishimasu H; Nakagawa H; Ishitani R; Kojima H; Nureki O; Aoki J; Nagano T
    J Med Chem; 2020 Mar; 63(6):3188-3204. PubMed ID: 32134652
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Plasma lysophosphatidic acid level and serum autotaxin activity are increased in liver injury in rats in relation to its severity.
    Watanabe N; Ikeda H; Nakamura K; Ohkawa R; Kume Y; Tomiya T; Tejima K; Nishikawa T; Arai M; Yanase M; Aoki J; Arai H; Omata M; Fujiwara K; Yatomi Y
    Life Sci; 2007 Sep; 81(12):1009-15. PubMed ID: 17850827
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lysoglycerophospholipids in chronic inflammatory disorders: the PLA(2)/LPC and ATX/LPA axes.
    Sevastou I; Kaffe E; Mouratis MA; Aidinis V
    Biochim Biophys Acta; 2013 Jan; 1831(1):42-60. PubMed ID: 22867755
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Autotaxin-Lysophosphatidic Acid: From Inflammation to Cancer Development.
    Valdés-Rives SA; González-Arenas A
    Mediators Inflamm; 2017; 2017():9173090. PubMed ID: 29430083
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Autotaxin, Pruritus and Primary Biliary Cholangitis (PBC).
    Sun Y; Zhang W; Evans JF; Floreani A; Zou Z; Nishio Y; Qi R; Leung PS; Bowlus CL; Gershwin ME
    Autoimmun Rev; 2016 Aug; 15(8):795-800. PubMed ID: 27019050
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Involvement of the lysophosphatidic acid-generating enzyme autotaxin in lymphocyte-endothelial cell interactions.
    Nakasaki T; Tanaka T; Okudaira S; Hirosawa M; Umemoto E; Otani K; Jin S; Bai Z; Hayasaka H; Fukui Y; Aozasa K; Fujita N; Tsuruo T; Ozono K; Aoki J; Miyasaka M
    Am J Pathol; 2008 Nov; 173(5):1566-76. PubMed ID: 18818380
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The role and therapeutic potential of the autotaxin-lysophosphatidate signalling axis in breast cancer.
    Teo K; Brunton VG
    Biochem J; 2014 Oct; 463(1):157-65. PubMed ID: 25195735
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Structural Basis for Inhibition of Human Autotaxin by Four Potent Compounds with Distinct Modes of Binding.
    Stein AJ; Bain G; Prodanovich P; Santini AM; Darlington J; Stelzer NM; Sidhu RS; Schaub J; Goulet L; Lonergan D; Calderon I; Evans JF; Hutchinson JH
    Mol Pharmacol; 2015 Dec; 88(6):982-92. PubMed ID: 26371182
    [TBL] [Abstract][Full Text] [Related]  

  • 59. ATX-LPA axis induces expression of OPN in hepatic cancer cell SMMC7721.
    Zhang R; Zhang Z; Pan X; Huang X; Huang Z; Zhang G
    Anat Rec (Hoboken); 2011 Mar; 294(3):406-11. PubMed ID: 21337710
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Development and therapeutic potential of autotaxin small molecule inhibitors: From bench to advanced clinical trials.
    Matralis AN; Afantitis A; Aidinis V
    Med Res Rev; 2019 May; 39(3):976-1013. PubMed ID: 30462853
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.